Tumor vaccines for breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2009-05-01 / Cancer Invest. 2009 May;27(4):361-8Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro
/in Breast Cancer, Dendritic Cells, International Publications /von 2009-01-01 / Cell. Immunol. 2009;257(1-2):23-31Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
/in Breast Cancer, Dendritic Cells, International Publications, IOZK Veröffentlichungen /von 2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-900Effect of combined therapy with the antiestrogen agent toremifene and local hyperthermia on breast cancer cells implanted in nude mice
/in Breast Cancer, Hyperthermia, International Publications /von 2008-09-27 / Surg. Today 2008;38(10):911-20Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy
/in Breast Cancer, International Publications /von 2008-09-01 / J. Immunol. 2008 Sep;181(5):3690-7Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2
/in Breast Cancer, Dendritic Cells, International Publications /von 2008-07-09 / Vaccine 2008 Aug;26(36):4716-24Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells
/in Breast Cancer, International Publications /von 2008-07-01 / J. Immunol. 2008 Jul;181(1):808-21Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha
/in Breast Cancer, Dendritic Cells, International Publications /von 2008-06-27 / BMC Immunol. 2008 Jun;9:32Cancer immunotherapy using in vitro genetically modified targeted dendritic cells
/in Breast Cancer, International Publications /von 2008-05-15 / Cancer Res. 2008 May;68(10):3854-62
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de